JANESVILLE, Wis., May 23, 2022 – SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, today announced Chris Vessell has joined as General Manager of the Therapeutics Division. In this role, he will be responsible for developing and building the team dedicated to SHINE’s strategy and offerings around non-carrier-added lutetium-177 for cancer therapies.
SHINE to supply n.c.a. Lu-177 for the clinical development of ImaginAb investigational radiopharmaceuticals
SHINE Medical Technologies LLC today announced that it has entered a multi-year contract with the University of Missouri Research Reactor, or MURR®, for irradiation of ytterbium-176.
SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries
SHINE Medical Technologies LLC today announced that the company has broken ground on a new 54,000-square-foot facility that will house its corporate headquarters and a large-scale production facility for the Therapeutics division it established last year.
SHINE announced that its Therapeutics division has made its first commercial sales of lutetium-177 to multiple customers. Lutetium-177, or Lu-177, is a therapeutic isotope in demand by clinical trial sponsors because of its potential to revolutionize the treatment of cancer patients.
SHINE Medical Technologies LLC, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare today announced the production of patient doses of the therapeutic isotope lutetium-177 (Lu-177).